Crucell inks $449M deal to create largest independent vaccine maker
Amsterdam-based Crucell said it has inked a deal to buy Switzerland's Berna Biotech and create one of the world's biggest drug development operations focused on vaccines. The merger is aimed at making the combined operation more competitive with the likes of GlaxoSmithKline, Sanofi-Aventis and Merck. The acquisition will add Berna's vaccines for hepatitis B, respiratory and travel ailments.
- read this article from the Financial Times for more information
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
